MCID: LBY004
MIFTS: 40

Labyrinthitis malady

Categories: Ear diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Labyrinthitis

Aliases & Descriptions for Labyrinthitis:

Name: Labyrinthitis 12 42 14 69
Labyrinthine Disorder 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1468
ICD10 33 H83.0 H83.09
ICD9CM 35 386.3 386.30
MeSH 42 D007762
UMLS 69 C0022893

Summaries for Labyrinthitis

Disease Ontology : 12 An otitis interna which involves inflammation of the labyrinths.

MalaCards based summary : Labyrinthitis, also known as labyrinthine disorder, is related to purulent labyrinthitis and viral labyrinthitis, and has symptoms including earache and vertigo. An important gene associated with Labyrinthitis is CRLF1 (Cytokine Receptor Like Factor 1). The drugs Betahistine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and testes, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Wikipedia : 71 Labyrinthitis, also known as vestibular neuritis, is inflammation of the inner ear. It results in... more...

Related Diseases for Labyrinthitis

Diseases in the Labyrinthitis family:

Viral Labyrinthitis

Diseases related to Labyrinthitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
id Related Disease Score Top Affiliating Genes
1 purulent labyrinthitis 12.2
2 viral labyrinthitis 12.1
3 toxic labyrinthitis 12.1
4 focal labyrinthitis 12.1
5 serous labyrinthitis 12.0
6 bilateral hypoactive labyrinth 11.8
7 bilateral hyperactive labyrinth 11.8
8 unilateral hyperactive labyrinth 11.8
9 unilateral hypoactive labyrinth 11.7
10 inner ear disease 11.6
11 meniere's disease 11.1
12 vestibular neuronitis 10.8
13 meningitis 10.2
14 otitis media 10.2
15 mastoiditis 10.0
16 von willebrand disease, platelet-type 10.0 EPB41 IGBP1
17 suppurative otitis media 9.9
18 sensorineural hearing loss 9.9
19 cholesteatoma 9.9
20 mumps 9.8
21 pneumococcal meningitis 9.8
22 otosclerosis 9.8
23 endotheliitis 9.7
24 cerebritis 9.7
25 autoimmune inner ear disease 9.7
26 congenital cytomegalovirus 9.7
27 pneumonia 9.7
28 thrombosis 9.7
29 facial paralysis 9.7
30 influenza 9.7
31 herpes simplex 9.7
32 sudden sensorineural hearing loss 9.7
33 headache 9.7
34 osteoporosis 9.5
35 cat-scratch disease 9.5
36 relapsing polychondritis 9.5
37 psoriasis 9.5
38 hypotonia 9.5
39 wegener granulomatosis 9.5
40 hemorrhagic fever with renal syndrome 9.5
41 dermoid cyst 9.5
42 neurosarcoidosis 9.5
43 diphtheria 9.5
44 anorexia nervosa 9.5
45 vestibular disease 9.5
46 encephalitis 9.5
47 panic disorder 9.5
48 ulcerative colitis 9.5
49 cavernous sinus thrombosis 9.5
50 sickle cell disease 9.5

Comorbidity relations with Labyrinthitis via Phenotypic Disease Network (PDN): (show all 22)


Anxiety Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Benign Paroxysmal Positional Nystagmus
Bronchitis Cerebrovascular Disease
Chronic Myocardial Ischemia Esophagitis
Generalized Atherosclerosis Hypertension, Essential
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Ischemic Heart Disease
Meniere's Disease Otitis Media
Pathologic Nystagmus Peripheral Vertigo
Transient Cerebral Ischemia Vertebral Artery Insufficiency
Vestibular Nystagmus Viral Labyrinthitis

Graphical network of the top 20 diseases related to Labyrinthitis:



Diseases related to Labyrinthitis

Symptoms & Phenotypes for Labyrinthitis

UMLS symptoms related to Labyrinthitis:


earache, vertigo

GenomeRNAi Phenotypes related to Labyrinthitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.65 EPB41
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.65 EPB41
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.65 HEY2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.65 HEY2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.65 EPB41
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.65 HEY2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.65 EPB41
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.65 HEY2 EPB41
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.65 EPB41
10 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.17 IGBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.17 IGBP1 NCS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.17 NCS1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.17 IGBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.17 IGBP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.17 NCS1

Drugs & Therapeutics for Labyrinthitis

Drugs for Labyrinthitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betahistine Approved Phase 4 5638-76-6 2366
2
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
3
Dimenhydrinate Approved Phase 4,Phase 3 523-87-5 441281
4 Piracetam Approved Phase 4 7491-74-9
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
7
Ethanol Approved Phase 4 64-17-5 702
8
Glycerol Approved, Experimental Phase 4 56-81-5 753
9
Phenol Approved, Experimental Phase 4 108-95-2 996
10
Thymol Approved Phase 4 89-83-8 6989
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
13
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
14
Calcium carbonate Approved Phase 4 471-34-1
15
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
16
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
18
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
19
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
20
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
21
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
22
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
23 Anticoagulants Phase 4
24 Antimetabolites Phase 4,Phase 3
25 Fibrinolytic Agents Phase 4
26 Glucuronyl glucosamine glycan sulfate Phase 4
27 Hypoglycemic Agents Phase 4
28 Hypolipidemic Agents Phase 4
29 Lipid Regulating Agents Phase 4
30 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Pharmaceutical Solutions Phase 4,Phase 2
32
Histamine Phosphate Phase 4,Phase 3 51-74-1 65513
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Vasodilator Agents Phase 4,Phase 2,Phase 1
35 Central Nervous System Stimulants Phase 4
36 Phosphodiesterase Inhibitors Phase 4,Phase 2
37 Purinergic P1 Receptor Antagonists Phase 4
38 Antiemetics Phase 4,Phase 2,Phase 3
39 Autonomic Agents Phase 4,Phase 2,Phase 3
40 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Histamine Antagonists Phase 4,Phase 3
42 Histamine H1 Antagonists Phase 4,Phase 3
43 Dopamine Agents Phase 4
44 Dopamine Antagonists Phase 4
45 Dopamine D2 Receptor Antagonists Phase 4
46 Antioxidants Phase 4,Phase 1,Phase 2
47 Micronutrients Phase 4
48 Nicotinic Acids Phase 4
49 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Tocopherols Phase 4

Interventional clinical trials:

(show top 50) (show all 146)
id Name Status NCT ID Phase
1 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4
2 Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Completed NCT02718846 Phase 4
3 Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy Completed NCT00160238 Phase 4
5 Effect of Caffeine Intake in Vestibular Function Completed NCT02825199 Phase 4
6 Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo Completed NCT01890538 Phase 4
7 Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Completed NCT02253524 Phase 4
8 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4
9 Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4
10 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Recruiting NCT02530931 Phase 4
11 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Recruiting NCT02529475 Phase 4
12 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4
13 Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV Recruiting NCT02031692 Phase 4
14 A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation Withdrawn NCT00474409 Phase 4
15 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3
16 Conventional Versus Virtual Reality Based Vestibular Rehabilitation Completed NCT01442623 Phase 2, Phase 3
17 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
18 Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease Completed NCT00802529 Phase 2, Phase 3
19 The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo Completed NCT02029508 Phase 3
20 Promethazine vs. Lorazepam for Treatment of Vertigo Completed NCT01827293 Phase 3
21 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT01366430 Phase 3
22 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
23 Canalith Repositioning Procedure for BPPV in Primary Care Completed NCT00182273 Phase 3
24 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
25 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Recruiting NCT02717442 Phase 3
26 Study of Lamotrigine to Treat Ménière's Disease Recruiting NCT02158585 Phase 3
27 Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin Recruiting NCT02112578 Phase 3
28 Rizatriptan for Episodic Dizziness in Vestibular Migraine Recruiting NCT02447991 Phase 2, Phase 3
29 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Active, not recruiting NCT02612337 Phase 3
30 A 6-Month Extension Study of OTO-104 in Meniere's Disease Enrolling by invitation NCT02768662 Phase 3
31 A 6-Month Extension Study of OTO-104 in Meniere's Disease Enrolling by invitation NCT02706730 Phase 3
32 Caroverin and Inner Ear Diseases Suspended NCT01174979 Phase 3
33 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3
34 Famvir for Treatment of Hearing in Unilateral Meniere's Disease Terminated NCT01526408 Phase 3
35 Visual Feedback Goggle for Positional Vertigo Treatment Unknown status NCT00729885 Phase 1, Phase 2
36 Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy Unknown status NCT02247648 Phase 2
37 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2
38 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2
39 A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom Completed NCT02265393 Phase 2
40 OTO-104 for the Treatment of Meniere's Disease Completed NCT01412177 Phase 2
41 Sildenafil For Meniere's Disease Completed NCT00145483 Phase 2
42 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2
43 A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Completed NCT02299804 Phase 2
44 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT02046980 Phase 2
45 Effect of V0251 in Acute Vertigo Completed NCT01583738 Phase 2
46 Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT00000359 Phase 2
47 A Trial of Booklet Based Self Management of Dizziness Completed NCT00732797 Phase 2
48 Traction Manipulation of Upper Cervical Spine on Cervicogenic Dizziness Recruiting NCT02772042 Phase 1, Phase 2
49 Open Label Study of OTO-104 in Subjects With Meniere's Disease Active, not recruiting NCT02740387 Phase 2
50 Latanoprost for the Treatment of Menière's Disease Active, not recruiting NCT01973114 Phase 2

Search NIH Clinical Center for Labyrinthitis

Cochrane evidence based reviews: labyrinthitis

Genetic Tests for Labyrinthitis

Anatomical Context for Labyrinthitis

MalaCards organs/tissues related to Labyrinthitis:

39
Eye, Bone, Testes, Endothelial, Brain, Bone Marrow

Publications for Labyrinthitis

Articles related to Labyrinthitis:

(show top 50) (show all 238)
id Title Authors Year
1
Deterioration of Vestibular Cells in Labyrinthitis. ( 27881797 )
2017
2
Does Otosclerosis Affect Dark and Transitional Cells in the Human Vestibular Labyrinth? ( 27851656 )
2017
3
Early Postoperative Imaging of the Labyrinth by Cone Beam CT After Stapes Surgery for Otosclerosis With Correlation to Audiovestibular Outcome. ( 28068300 )
2017
4
Quantitative Assessment of Cochlear Histopathologic Findings in Patients With Suppurative Labyrinthitis. ( 26987015 )
2016
5
Suppurative labyrinthitis associated with otitis media: 26 years' experience. ( 26718959 )
2016
6
Labyrinthitis ossificans after meningitis: Superiority of high-resolution magnetic resonance imaging in demonstration of disease extent compared to high-resolution computed tomography. ( 27114680 )
2016
7
Nystagmus in patients with unilateral acute otitis media complicated by serous labyrinthitis. ( 26797398 )
2016
8
Pathologic Findings of the Cochlea in Labyrinthitis Ossificans Associated with the Round Window Membrane. ( 27221575 )
2016
9
Pneumolabyrinth with Labyrinthitis as the Suspected Cause. ( 27115607 )
2016
10
Cochlear changes in serous labyrinthitis associated with silent otitis media: A human temporal bone study. ( 26954857 )
2016
11
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. ( 25724219 )
2015
12
Cortical hot spots and labyrinths: why cortical neuromodulation for episodic migraine with aura should be personalized. ( 25798103 )
2015
13
Refractory Positional Vertigo With Apogeotropic Horizontal Nystagmus After Labyrinthitis: Surgical Treatment and Identification of Dysmorphic Ampullae. ( 26208126 )
2015
14
Rapidly Destructive Autoimmune Labyrinthitis Associated With Ulcerative Colitis. ( 26385058 )
2015
15
Labyrinthitis Ossificans: On the Mechanism of Perilabyrinthine Bone Remodeling. ( 25757630 )
2015
16
The Impact of Postmeningitic Labyrinthitis Ossificans on Speech Performance After Pediatric Cochlear Implantation. ( 26536413 )
2015
17
Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. ( 25738715 )
2015
18
The incidence of tympanogenic labyrinthitis ossificans. ( 25075947 )
2014
19
Bilateral sensorineural hearing loss and labyrinthitis ossificans secondary to neurosarcoidosis. ( 25189997 )
2014
20
Three-dimensional cone beam computed tomography imaging of the membranous labyrinth in patients with Meniere's disease. ( 25220723 )
2014
21
PAN's Labyrinth: Molecular Biology of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) PAN RNA, a Multifunctional Long Noncoding RNA. ( 25375885 )
2014
22
Longitudinal assessment of endolymphatic hydrops with contrast-enhanced magnetic resonance imaging of the labyrinth. ( 24770407 )
2014
23
High-resolution 3-D T2-weighted imaging in the diagnosis of labyrinthitis ossificans: emphasis on subtle cochlear involvement. ( 23843131 )
2013
24
Geometrical and volume changes of the membranous vestibular labyrinth in guinea pigs with endolymphatic hydrops. ( 23817074 )
2013
25
Clinical outcome after cochlear implantation in patients with unilateral hearing loss due to labyrinthitis ossificans. ( 23921941 )
2013
26
Labyrinthitis ossificans in a cochlear implant patient with Usher syndrome. ( 23455060 )
2013
27
Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? ( 23930669 )
2013
28
A rat in the labyrinth of anorexia nervosa: contributions of the activity-based anorexia rodent model to the understanding of anorexia nervosa. ( 23354987 )
2013
29
Tuberculous otitis media with facial paralysis combined with labyrinthitis. ( 24653900 )
2013
30
Herniation of the membranous labyrinth into the horizontal semicircular canal is correlated with impaired caloric response in MAcniA"re's disease. ( 22918115 )
2012
31
Intracranial dermoid cyst ruptured into the membranous labyrinth causing sudden sensorineural hearing loss: CT and MR imaging findings. ( 21920864 )
2012
32
Acute labyrinthitis secondary to aural tick infestation. ( 23077807 )
2012
33
Apoptosis of the fibrocytes type 1 in the spiral ligament and blood labyrinth barrier disturbance cause hearing impairment in murine cerebral malaria. ( 22297132 )
2012
34
End-stage labyrinthitis with extensive erosion of the bony labyrinth. ( 22377652 )
2012
35
Endolymphatic hydrops and blood-labyrinth barrier in MAcniA"re's disease. ( 21198346 )
2011
36
Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. ( 21526906 )
2011
37
Effect of Ginkgo biloba extract on endotoxin-induced labyrinthitis. ( 21592590 )
2011
38
Radiology quiz case 2. Labyrinthitis ossificans secondary to suppurative labyrinthitis. ( 21422319 )
2011
39
Labyrinthitis ossificans secondary to autoimmune inner ear disease: a previously unreported condition. ( 20416474 )
2010
40
Deafness due to haemorrhagic labyrinthitis and a review of relapses in Streptococcus suis meningitis. ( 20358139 )
2010
41
Labyrinthitis ossificans. ( 19300296 )
2009
42
Posttraumatic labyrinthitis ossificans with perilymphatic fistulization. ( 19862674 )
2009
43
Labyrinthitis ossificans: how accurate is MRI in predicting cochlear obstruction? ( 19393413 )
2009
44
Labyrinthitis ossificans in a child with sickle cell disease: CT and MRI findings. ( 19415252 )
2009
45
Endolymphatic hydrops of the labyrinth visualized on noncontrast MR imaging: a case report. ( 19336989 )
2009
46
Serous labyrinthitis as a manifestation of cat scratch disease: a case report. ( 20519021 )
2009
47
Meningitis resulting in hearing loss and labyrinthitis ossificans - does the causative organism matter? ( 18246540 )
2008
48
Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths. ( 19073416 )
2008
49
Labyrinthitis related to Wegener granulomatosis: magnetic resonance imaging findings. ( 18097336 )
2008
50
HOXA13 Is essential for placental vascular patterning and labyrinth endothelial specification. ( 18483557 )
2008

Variations for Labyrinthitis

Expression for Labyrinthitis

Search GEO for disease gene expression data for Labyrinthitis.

Pathways for Labyrinthitis

GO Terms for Labyrinthitis

Cellular components related to Labyrinthitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 postsynaptic density GO:0014069 8.62 EPB41 NCS1

Sources for Labyrinthitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....